February 12, 2020 / 12:19 PM / 9 days ago

BRIEF-Allena Pharma Announces Streamlined Design For Urirox-2, Second Pivotal Clinical Trial Of Reloxaliase For Enteric Hyperoxaluria

Feb 12 (Reuters) - Allena Pharmaceuticals Inc:

* ALLENA PHARMACEUTICALS ANNOUNCES STREAMLINED DESIGN FOR URIROX-2, SECOND PIVOTAL CLINICAL TRIAL OF RELOXALIASE FOR ENTERIC HYPEROXALURIA

* ALLENA PHARMACEUTICALS - PLANS TO SUBMIT A PROTOCOL AMENDMENT AND ASSOCIATED STUDY DOCUMENTS FOR REVISED TRIAL DESIGN IN Q1 OF 2020 FOR URIROX-2

* ALLENA PHARMACEUTICALS INC - INTERIM ANALYSIS IS PROJECTED FOR Q3 OF 2021 FOR URIROX-2 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below